Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VERA

Vera Therapeutics Inc

Dec 17 • 04:00PM ET

48.53

+0.23 0.48 %

Healthcare • Biotechnology • USA • NASD

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: IWM XBI VTI IWO VXF IBB SCHA VTWO FESM DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	23.87%	Shs Outstand	63.89M	Perf Week	9.45%
Market Cap	3.40B	Forward P/E	-	EPS next Y	-4.67	Insider Trans	1.25%	Shs Float	53.34M	Perf Month	64.73%
Enterprise Value	2.98B	PEG	-	EPS next Q	-1.30	Inst Own	83.58%	Short Float	20.28%	Perf Quarter	84.24%
Income	-251.94M	P/S	-	EPS this Y	-66.21%	Inst Trans	0.49%	Short Ratio	6.67	Perf Half Y	131.98%
Sales	0.00M	P/B	7.77	EPS next Y	-2.22%	ROA	-56.87%	Short Interest	10.82M	Perf YTD	14.76%
Book/sh	6.24	P/C	6.84	EPS next 5Y	-0.64%	ROE	-73.25%	52W High	51.19 -5.20%	Perf Year	10.17%
Cash/sh	7.10	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-52.97%	52W Low	18.53 161.90%	Perf 3Y	171.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.85% 7.74%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.44%	Oper. Margin	-	ATR (14)	2.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	77.71	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.09	EPS Q/Q	-48.06%	SMA20	23.56%	Beta	1.14	Target Price	69.77
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	46.76%	Rel Volume	0.54	Prev Close	48.30
Employees	112	LT Debt/Eq	0.19	Earnings	Nov 05 BMO	SMA200	86.63%	Avg Volume	1.62M	Price	48.53
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% -	Trades		Volume	875,632	Change	0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
07:45PM	Loading…
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
07:29AM	Loading…
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Loading…
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 04:38PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Option Exercise	2.90	17,500	50,694	153,578	Jan 10 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Sale	41.74	17,500	730,535	143,603	Jan 10 04:06 PM
MARSHALL FORDYCE	Director	Jan 08 '25	Proposed Sale	42.10	17,500	736,750		Jan 08 04:22 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 19 '24	Option Exercise	2.90	57,661	167,032	143,603	Dec 20 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience